August 29, 2018

Our Therapies

Ultra-Long-Acting Oral Dosing is Achievable

Our Team has developed the first ultra-long-acting pill that lasts a week or longer and can provide a wide range of medicines in a familiar oral capsule form. Once inside the stomach, the capsule delivers steady amounts of medicine for seven days or more.  Our once-weekly product has safely demonstrated gastric residence with predictable pharmacokinetics in humans.  There are no other oral products which provide ultra-long-acting therapeutic coverage or a controlled, steady delivery of medicine which can reduce side effects and improve drug efficacy, resulting in measurable health outcomes.

  • Advantages in systemic, non-systemic, and local target delivery due to continuous & steady delivery
  • Possibility of reducing total dose while maintaining efficacy (non-inferiority)
  • Reducing Cmax can improve side effects
  • Forgiveness if delayed administration
  • Reduced healthcare costs through better pharmacology and measurable health outcomes
  • Patient freedom form the burden of daily medications
  • Adaptable for wide range of single agents and combinations
  • Discreet user controlled administration
  • Reduced pill burden
  • Reduced caregiver burden
  • Superior Pharmacology for existing Agents
  • Loss of Exclusivity (LOE)
  • Combination Products
  • Local GI Delivery
  • Non-systemic Delivery Enhanced Continuous Release
  • Schizophrenia


    Schizophrenia is associated with significant health, social and economic concerns. Individuals with schizophrenia often have difficulty staying on their medications, resulting in relapse rates in as many as 75 percent of patients diagnosed with the disease. Schizophrenia has been associated with high rates of co-occurring medical conditions and an increased risk of premature mortality. Improving access to treatment to reduce the potential for relapse is critical. Lyndra is advancing toward filing an application with the FDA to begin clinical trials on a once-a-week dose of risperidone, a medication used to treat schizophrenia.

  • Alzheimer's Disease

    Alzheimer's Disease

    Nearly six million Americans are living with Alzheimer’s disease and more than 16 million Americans provide unpaid care for people with Alzheimer’s or other dementias. Lyndra partnered with Allergan to develop an oral once-weekly capsule to deliver sustained-release memantine hydrochloride, a drug for Alzheimer’s disease. An ultra-long-acting treatment can help extend the time a patient can perform simple daily tasks without full supervision, alleviating stress, reducing costs and potentially delaying the decision to enter patients into nursing homes.

  • Opioid Use Disorder

    Opioid Use Disorder

    More than 47,000 Americans died of opioid overdose in 2017 and 2 million more Americans live with addiction to opioids. The National Institute on Drug Abuse (NIDA) has called for new treatment strategies that help address the current opioid crisis, including new formulations of existing medications to improve treatment access and adherence. Lyndra is developing a once-weekly oral dosage of buprenorphine, an FDA-approved medication-assisted treatment (MAT) that improves outcomes and saves lives in patients with opioid use disorder.

  • Malaria Vector Control

    Malaria Vector Control

    Nearly half of the world’s population is at risk of malaria and in 2017 an estimated 435,000 deaths due to malaria occurred globally. Efforts at eliminating malaria are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. Lyndra is developing a weekly dosage of ivermectin, a drug that targets malaria-transmitting mosquitoes, that can interrupt the vector transmission of malaria for up to 14 days. The drug could boost the efficacy of mass drug administration and help eliminate malaria.